Enhancing the growth of natural eyelashes: The mechanism of bimatoprost-induced eyelash growth

Dermatologic Surgery

Volumn 36, Issue 9, 2010, Pages 1361-1371

  Cohen, Joel L ^a,b  

^a AboutSkin Dermatology and DermSurgery PC   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; LATISSE; TRAVOPROST; UNCLASSIFIED DRUG;

BURNING SENSATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRY EYE; EYE PAIN; EYELASH; GLAUCOMA; GROWTH REGULATION; HAIR FOLLICLE; HAIR GROWTH; HAIR ROOT; HAIR TEXTURE; HUMAN; HYPEREMIA; HYPOTRICHOSIS; INTRAOCULAR HYPERTENSION; MELANOGENESIS; NONHUMAN; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; VISUAL DISORDER;

AMIDES; CLOPROSTENOL; EYELASHES; HUMANS;

EID: 77956274118     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2010.01522.x     Document Type: Review

References (48)

1. Synnott A. The beauty mystique. Facial Plast Surg 2006 22 : 163 174.
2. McCurdy JA Jr. Beautiful eyes: characteristics and application to aesthetic surgery. Facial Plast Surg 2006 22 : 204 214.
3. Mulhern R, Fieldman G, Hussey T, et al. Do cosmetics enhance female Caucasian facial attractiveness? Int J Cosmet Sci 2003 25 : 199 205.
4. DeMello M. Facial hair. In : DeMello M, editor. Encyclopedia of Body Adornment. Westport, CT : Greenwood Publishing Group 2007. p. 109.
5. Batchelor D. Hair and cancer chemotherapy: consequences and nursing care-a literature study. Eur J Cancer Care (Engl) 2001 10 : 147 163.
6. Hunt N, McHale S. The psychological impact of alopecia. BMJ 2005 331 : 951 953.
7. Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007 6 : 45 52.
8. Shaikh MY, Bodla AA. Hypertrichosis of the eyelashes from prostaglandin analog use: a blessing or a bother to the patient? [letter]. J Ocul Pharmacol Ther 2006 22 : 76 7.
9. Draelos ZD. Special considerations in eye cosmetics. Clin Dermatol 2001 19 : 424 430.
10. Randall VA. Hormonal regulation of hair follicles exhibits a biological paradox. Semin Cell Dev Biol 2007 18 : 274 285.
11. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol 2000 118 : 718 719.
12. Khong JJ, Casson RJ, Huilgol SC, et al. Madarosis. Surv Ophthalmol 2006 51 : 550 560.
13. O'Donoghue MN. Eye cosmetics. Dermatol Clin 2000 18 : 633 639.
14. Maxwell A. Eyes open wide with these lash extensions. Available at :. Accessed December 2, 2009.
15. Straub PM. Replacing facial hair. Facial Plast Surg 2008 24 : 446 452.
16. Hernández-Zendejas G, Guerrerosantos J. Eyelash reconstruction and aesthetic augmentation with strip composite sideburn graft. Plast Reconstr Surg 1998 101 : 1978 1980.
17. Latisse [package insert]. Irvine, CA : Allergan, Inc. 2008.
18. Moses RA. The eyelids. In : Moses RA, editor. Adler's Physiology of the Eye: Clinical Application. 5th ed. St. Louis, MO : C.V. Mosby Company 1970. p. 1 16.
19. Elder MJ. Anatomy and physiology of eyelash follicles: relevance to lash ablation procedures. Ophthal Plast Reconstr Surg 1997 13 : 21 5.
20. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002 47 (Suppl 1) : S185 202.
21. Na JI, Kwon OS, Kim BJ, et al. Ethnic characteristics of eyelashes: a comparative analysis in Asian and Caucasian females. Br J Dermatol 2006 155 : 1170 1176.
22. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999 341 : 491 497.
23. Habif TP. Hair diseases. In : Habif TP, editor. Clinical Dermatology: A Color Guide to Diagnosis and Treatment. 4th ed. St. Louis, MO : Mosby, Inc. 2003.
24. Randall VA. Androgens and hair growth. Dermatol Ther 2008 21 : 314 328.
25. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004 150 : 186 194.
26. Buhl AE. Minoxidil's action in hair follicles. J Invest Dermatol 1991 96 : 73S 4S.
27. Wolf R, Matz H, Zalish M, et al Prostaglandin analogs for hair growth: great expectations. Dermatology Online Journal 2003;9:7. Available at :. Accessed September 10, 2009.
28. Propecia [package insert]. Whitehouse Station, NJ : Merck & Co., Inc. 2007.
29. Woodward DF, Liang Y, Krauss AH-P. Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol 2008 153 : 410 419.
30. Smyth EM, Burke A, FitzGerald G. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In : Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York : The McGraw-Hill Companies, Inc. 2006.
31. ™). Surv Ophthalmol 2001 45 (Suppl 4) : S337 45.
32. Allergan, Inc. Lumigan [package insert]. Irvine, CA : Allergan, Inc. 2006.
33. Williams RD, Cohen JS, Gross RL, et al, for the Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol 2008 92 : 1387 1392.
34. Woodward DFC, Carling RW, Cornell CL, et al. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther 2008 120 : 71 80.
35. Krauss AH-P, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol 2004 49 (Suppl 1) : S5 11.
36. Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol 2008 154 : 1079 1093.
37. Tosti A, Pazzaglia M, Voudouris S, et al. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 2004 51 : S149 50.
38. Colombe L, Michelet J-F, Bernard BA. Prostanoid receptors in anagen human hair follicles. Exp Dermatol 2008 17 : 63 72.
39. Higginbotham EJ, Schuman JS, Goldberg I, et al, for the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002 120 : 1286 1293.
40. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008 53 (Suppl 1) : S93 105.
41. Centofanti M, Oddone F, Chimenti S, et al. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am J Ophthalmol 2006 142 : 1059 1060.
42. Gandolfi S, Simmons ST, Sturm R, et al, for the Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001 18 : 110 121.
43. Kapur R, Osmanovic S, Toyran S, et al. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol 2005 123 : 1541 1546.
44. Galloway GD, Eke T, Broadway DC. Periocular cutaneous pigmentary changes associated with bimatoprost use. Arch Ophthalmol 2005 123 : 1609 1610.
45. Stjernschantz JW, Albert DM, Hu D-N, et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002 47 (Suppl 1) : 162S 75S.
46. Hart J, Shafranov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol 2004 137 : 756 757.
47. Smith S, Fagien S, Somogyi C, et al Eyelash growth in subjects treated with bimatoprost ophthalmic solution 0.03%; a multicenter, randomized, double-masked, vehicle-controlled, parallel study. Poster presented at: American Academy of Dermatology's 67th Annual Meeting; March 6-9, 2009; San Francisco, CA.
48. Brandt JD, VanDenburgh AM, Chen K, et al, for the Bimatoprost Study Group 1. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001 108 : 1023 1031.